Osteomyelitis - Epidemiology Forecast - 2032

Osteomyelitis - Epidemiology Forecast - 2032

DelveInsight’s ‘Osteomyelitis—Epidemiology Forecast—2032’ report delivers an in-depth understanding of osteomyelitis historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Osteomyelitis Disease Understanding

Osteomyelitis is an acute infection of the bone that can occur from direct or indirect invasion by a pathogen. Direct invasion is also referred to as exogenous or acute contagious osteomyelitis and can occur at any time if there is an open wound in the body. Indirect invasion is also referred to as endogenous or acute hematogenous osteomyelitis and usually occurs from the spread of systemic infection. Both of these types can potentially progress to sub-acute and chronic osteomyelitis. Acute osteomyelitis typically refers to an infection of less than 1-month duration, whereas chronic osteomyelitis refers to an infection that lasts longer than 4 weeks.

Osteomyelitis Epidemiology

The osteomyelitis epidemiology report provides insights into the historical and diagnosed incident patient pool and the forecasted trend for all seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The total diagnosed incident cases of osteomyelitis patients in the 7MM will increase during the study period, i.e., 2019–2032.

The disease epidemiology covered in the report provides historical as well as forecasted osteomyelitis symptoms epidemiology segmented as the total diagnosed incident cases of osteomyelitis, severity-specific diagnosed cases of osteomyelitis, gender-specific diagnosed cases of osteomyelitis, age-specific diagnosed cases of osteomyelitis, etiology-specific diagnosed cases of osteomyelitis, location-specific diagnosed cases of osteomyelitis, and laterality-specific diagnosed cases of osteomyelitis. The report includes the diagnosed incident cases scenario of osteomyelitis in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Osteomyelitis Epidemiology

The epidemiology segment also provides the osteomyelitis epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The diagnosed incident cases of osteomyelitis associated with the 7MM countries were around 161,500 in 2021.

As per the estimates, the United States has the highest number of diagnosed incident cases of osteomyelitis in 2021.

Among the EU5 countries, Germany had the highest number of diagnosed incident cases of osteomyelitis, followed by France in 2021. On the other hand, Spain had the lowest number of diagnosed incident cases, with about 2,300 cases in 2021.

Scope of the Report

The osteomyelitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.

The osteomyelitis epidemiology report and model provide an overview of osteomyelitis’ risk factors and global trends in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan).

The report provides insight into osteomyelitis’ historical and forecasted patient pool in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, and the UK), and Japan.

The report helps recognize the growth opportunities in the 7MM concerning the patient population.

The report assesses the disease risk and burden and highlights the unmet needs of osteomyelitis.

The report provides the segmentation of osteomyelitis epidemiology by the diagnosed incident cases of osteomyelitis in the 7MM.

The report provides the osteomyelitis epidemiology segmentation by severity-specific diagnosed cases of osteomyelitis in the 7MM.

The report provides the osteomyelitis epidemiology segmentation by gender-specific diagnosed cases of osteomyelitis in the 7MM.

The report provides the osteomyelitis epidemiology segmentation by age-specific diagnosed cases of osteomyelitis in the 7MM.

The report provides the osteomyelitis epidemiology segmentation by etiology-specific diagnosed cases of osteomyelitis in the 7MM.

The report provides the osteomyelitis epidemiology segmentation by location-specific diagnosed cases of osteomyelitis in the 7MM.

The report provides the osteomyelitis epidemiology segmentation by laterality-specific diagnosed cases of osteomyelitis in the 7MM.

Report Highlights

11-year forecast of osteomyelitis epidemiology

7MM Coverage

Total diagnosed incident cases of osteomyelitis

Severity-specific diagnosed cases of osteomyelitis

Gender-specific diagnosed cases of osteomyelitis

Age-specific diagnosed cases of osteomyelitis

Etiology-specific diagnosed cases of osteomyelitis

Location-specific diagnosed cases of osteomyelitis

Laterality-specific diagnosed cases of osteomyelitis

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

What are the major factors that will drive the change in the patient population in osteomyelitis during the forecast period (2019–2032)?

What are the key findings of osteomyelitis epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?

What would be the total number of osteomyelitis patients across the 7MM during the forecast period (2019–2032)?

Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?

At what CAGR the patient population is expected to grow in the 7MM during the forecast period (2019–2032)?

What are the disease risks, burdens, and unmet needs of the osteomyelitis market?

What are the current treatment patterns for osteomyelitis?

Reasons to buy

The osteomyelitis epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global osteomyelitis market.

Quantify patient populations in the global osteomyelitis market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for osteomyelitis therapeutics in each market covered.

Understand the magnitude of the osteomyelitis population by its diagnosed incidence.

Understand the magnitude of the osteomyelitis population by its severity-specific diagnosed cases.

Understand the magnitude of the osteomyelitis population by its gender-specific diagnosed cases.

Understand the magnitude of the osteomyelitis population by its age-specific diagnosed cases.

Understand the magnitude of the osteomyelitis population by its etiology-specific diagnosed cases.

Understand the magnitude of the osteomyelitis population by its location-specific diagnosed cases.

Understand the magnitude of the osteomyelitis population by its laterality-specific diagnosed cases.

The osteomyelitis epidemiology report and model were written and developed by Master’s and Ph.D. level epidemiologists.

The osteomyelitis epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

Patient segmentation

Disease risk and burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

Geographies Covered

The United States

The EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019–2032